Balance is good...I am for balance. I took the test from

New Post Public Reply Private Reply Replies (1) Message Board
Goosebumps craigakess #73312
679
Balance is good...I am for balance. I took the test from the article and scored a 3 on the test. I am curious to know if you read the article and took the test to see your balance Craigakess? Or maybe lack of balance?

So for your benefit and so you don’t have to read the whole article. I have a link direct to the article test for you. If you chose to take the test. You can just PM me your results and you don’t have to post them for all to see. Don’t want to hurt your reputation of not being a optimist or anything. I am courious to see if you are a self defined optimist at heart or just trying to fool me...and maybe others. But if you PM me I won’t tell. It will be in confidence. Since we have had conversations like this before. It will help us both to clear the air.

file:///var/mobile/Library/SMS/Attachments/d5/05/E3FDEA3B-7A59-404C-87B2-BCD8CFAE1FBC/IMG_9724.jpegP

By the way, when it comes to protecting our investment in CYDY. I will go to bat for us all and myself to protect it from bashers and shorts and anyone who seems suspect in their motives.

Why would I do this? It’s because I believe completely in Leronlimab and feel all the bashing and short attacks have belittled this company and taken legitimacy away from a what should respected biotech based on the science alone. The management is just fine also. I am not a Nader Hater and hope he leads us to the promise land. To many doctors are on board with the science of this molecule for it not to have the utmost respect and I try to make sure that in my small insignificant way that it has that respect. It’s what I believe will help this drug overcome the doubt that others sew for all to read. Do I feel I need to protect our investment. Yes... I do!

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Frontera Energy Set to Release Quarterly Financial Results Soon

Updated Category News Views 253

Frontera Energy Announces First Quarter Financial Results Frontera Energy Corporation (TSX: FEC) has exciting news for its shareholders and interested investors. The Company is set to unveil its financial and operational results for the first quarter, wrapping up on March 31, 2025. This significant announcement will occur after the market closes on a forthcoming Thursday...

Continue Reading
The Rising Value of Contrast Media Injectors in Healthcare

Updated Category News Views 133

Exploring the Global Market for Contrast Media Injectors The global market for contrast media injectors is on the verge of substantial growth, with projections indicating it will reach $2.1 billion in the coming years. This anticipated growth, at a compound annual growth rate (CAGR) of 7.8% from 2025 through 2033, is primarily driven by ongoing advances in technology and...

Continue Reading
Beth Wozniak Sells nVent Electric Shares Worth $884K

Updated Category News Views 158

Beth Wozniak's Recent Stock Sale at nVent Electric Beth Wozniak, Chair & CEO of nVent Electric (NYSE:NVT), executed a significant insider sale recently, as revealed in a new SEC filing. This transaction involved the offloading of 7,597 shares, with a total value of approximately $884,822. Such movements in stock ownership often pique the interest of investors, prompting...

Continue Reading
Electoral Impact of Rising Home Prices on Kamala Harris' Campaign

Updated Category News Views 211

The Impact of Home Prices on the Upcoming Election As we approach the presidential election, the role that home prices play in shaping voter sentiments is becoming increasingly evident. Recent research has shown that fluctuations in the housing market can significantly affect how voters make their choices, particularly in crucial battleground states. Current Trends in...

Continue Reading
Iambic Therapeutics Welcomes Michael Secora as CFO and CDO

Updated Category News Views 134

Iambic Therapeutics Welcomes Michael Secora as CFO and CDO Iambic Therapeutics has announced an important leadership change, appointing Michael Secora, Ph.D., as its Chief Corporate Development Officer and Chief Financial Officer. This decision comes as Iambic continues its commitment to pioneering novel medicines through its innovative AI-driven drug discovery platform....

Continue Reading